---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010303"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:30:41.679409+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance

## Summary
- Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
- Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.
- LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.
- Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.
- Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares.

## SEC filing metadata
- accession: 0001493152-24-010303
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010303
- JSON: https://secwatch.observer/filing/0001493152-24-010303.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010303.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 18, 2024, Lantern Pharma Inc. (the "Company") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.